BOOST Pharma Co-founder and Chief Development Officer Lilian Walther Jallow presented at the 3rd ATMP Mini-Symposium at Lund University.
Lilian shared BOOST Pharma’s work advancing BT-101 for severe pediatric Osteogenesis Imperfecta (OI), including the academic and clinical foundations behind the program’s development.
The symposium brought together researchers and industry representatives from across the Nordic advanced therapy community for scientific exchange and collaboration.